NIKKEI 225
38,274.05 -131.61 (-0.34%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
79.13 +0.13 (+0.16%) GOLD FUTURES
2,330.20 +27.30 (+1.19%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
46,110.98 -1,928.54 (-4.01%)
Bristol-Myers Squibb Company (BMY.MX)
| Previous close | 762.50 |
| Open | 758.75 |
| Bid | 753.50 x 1400 |
| Ask | 773.48 x 3800 |
| Day's range | 758.75 - 758.75 |
| 52-week range | 758.75 - 1,218.58 |
| Volume | |
| Avg. volume | 2,736 |
| Market cap | 1.538T |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -52.73 |
| Earnings date | 26 Jul 2024 |
| Forward dividend & yield | 39.81 (5.25%) |
| Ex-dividend date | 04 Apr 2024 |
| 1y target est | N/A |
GlobeNewswireEditas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseasesCAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer
Insider MonkeyBristol-Myers Squibb Company (NYSE:BMY) Q1 2024 Earnings Call Transcript
Bristol-Myers Squibb Company (NYSE:BMY) Q1 2024 Earnings Call Transcript April 25, 2024 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is $-4.4, expectations were $-4.55. Bristol-Myers Squibb Company isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Bristol-Myers […]
ZacksBristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
